A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers

Gene Therapy

Volumn 4, Issue 3, 1997, Pages 264-267

  Evans, T J ^a   Brooks, L ^a,c   Farrell, P J ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Burkitt's lymphoma; EBNA; Epstein Barr virus; Nasopharyngeal carcinoma

Indexed keywords

GANCICLOVIR;

ARTICLE; BURKITT LYMPHOMA; CELL KILLING; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENE THERAPY; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PLASMID; PRIORITY JOURNAL; REPORTER GENE; TARGET CELL; TUMOR CELL; VIRUS GENE;

EID: 0030888538     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300392     Document Type: Article

References (23)

1. Vousden KH, Farrell PJ. Viruses and human cancer. Br Med Bull 1994; 50: 560-581.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe PM, Howley PM (eds). Fields Virology. Lippincott-Raven: Philadelphia, 1996, pp 2397-2446.
3. Wysokenski DA, Yates JL. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 1989; 63: 2657-2666.
4. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984; 81: 3806-3810.
5. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
6. Reisman D, Sugden B. Transactivation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986; 6: 3838-3846.
7. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol 1985; 5: 2533-2542.
8. Rawlins DR, Milman G, Hayward SD, Hayward GS Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985; 42: 859-868
9. Ambinder RF et al. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J Virol 1991; 65: 1466-1478.
10. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989; 63: 2644-2649.
11. Gahn TA, Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 1995; 69: 2633-2636.
12. Baer R et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310: 207-211.
13. Banerjee S, Livanos E, Vos JH. Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nat Med 1995; 1: 1303-1308.
14. Bodescot M, Perricaudet M, Farrell PJ. A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol 1987; 61: 3424-3430.
15. Klonjkowski B, Walls D, Gilardi-Hebenstreit P, Perricaudet M. Repression of the viral latent promoter BC-R2 in Epstein-Barr virus negative cell lines. Biochem Biophys Res Commun 1992; 189: 1695-1700.
16. Nilsson T, Sjoblom A, Masucci MG, Rymo L. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype. Virology 1993; 193: 774-785.
17. Starzl TE et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
18. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
19. Gutierrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein- Barr virus-associated neoplasia. Cancer Res 1996; 56: 969-972.
20. Busslinger M, Moschonas N, Flavell RA. Beta + thalassemia: aberrant splicing results from a single point mutation in an intron. Cell 1981; 27: 289-298.
21. Sugden B, Marsh K, Yates J. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 1985; 5: 410-413.
22. Evans TJ, Farrell PJ, Swaminathan S. Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol 1996; 70: 1695-1705.
23. Evans TJ, Jacquemin MG, Farrell PJ. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology 1995; 206: 866-877.